Latest SUPERSTRING CAPITAL MANAGEMENT LP Stock Portfolio
$139Million– No. of Holdings #35
SUPERSTRING CAPITAL MANAGEMENT LP Performance:
2026 Q1: -0.97%YTD: -0.97%2025: 60.47%
Performance for 2026 Q1 is -0.97%, and YTD is -0.97%, and 2025 is 60.47%.
About SUPERSTRING CAPITAL MANAGEMENT LP and 13F Hedge Fund Stock Holdings
On 2026-05-14, the fund reported it's updated stock portfolio. In the 13F Holdings report, SUPERSTRING CAPITAL MANAGEMENT LP reported an equity portfolio of $140 Millions as of 31 Mar, 2026.
The top stock holdings of SUPERSTRING CAPITAL MANAGEMENT LP are SMMT, IMVT, COGT. The fund has invested 12.1% of it's portfolio in SUMMIT THERAPEUTICS INC and 6.3% of portfolio in IMMUNOVANT INC .
The fund managers got completely rid off CIDARA THERAPEUTICS INC (CDTX), TERNS PHARMACEUTICALS INC (TERN) and DYNAVAX TECHNOLOGIES CORP (DVAX) stocks. They significantly reduced their stock positions in CENTURY THERAPEUTICS INC (IPSC), TAYSHA GENE THERAPIES INC (TSHA) and BRIGHT MINDS BIOSCIENCES INC (DRUG). SUPERSTRING CAPITAL MANAGEMENT LP opened new stock positions in SUMMIT THERAPEUTICS INC (SMMT), DEFINIUM THERAPEUTICS INC and VIR BIOTECHNOLOGY INC (VIR). The fund showed a lot of confidence in some stocks as they added substantially to GENMAB A/S (GMAB), TRAVERE THERAPEUTICS INC (TVTX) and CELLDEX THERAPEUTICS INC NEW (CLDX).
The top stock holdings of SUPERSTRING CAPITAL MANAGEMENT LP are SMMT, IMVT, COGT. The fund has invested 12.1% of it's portfolio in SUMMIT THERAPEUTICS INC and 6.3% of portfolio in IMMUNOVANT INC .
The fund managers got completely rid off CIDARA THERAPEUTICS INC (CDTX), TERNS PHARMACEUTICALS INC (TERN) and DYNAVAX TECHNOLOGIES CORP (DVAX) stocks. They significantly reduced their stock positions in CENTURY THERAPEUTICS INC (IPSC), TAYSHA GENE THERAPIES INC (TSHA) and BRIGHT MINDS BIOSCIENCES INC (DRUG). SUPERSTRING CAPITAL MANAGEMENT LP opened new stock positions in SUMMIT THERAPEUTICS INC (SMMT), DEFINIUM THERAPEUTICS INC and VIR BIOTECHNOLOGY INC (VIR). The fund showed a lot of confidence in some stocks as they added substantially to GENMAB A/S (GMAB), TRAVERE THERAPEUTICS INC (TVTX) and CELLDEX THERAPEUTICS INC NEW (CLDX).
SUPERSTRING CAPITAL MANAGEMENT LP Equity Portfolio Value
Last Reported on: 14 May, 2026
SUPERSTRING CAPITAL MANAGEMENT LP Annual Return Estimates Vs S&P 500
Our best estimate is that SUPERSTRING CAPITAL MANAGEMENT LP made a return of -0.97% in the last quarter. In trailing 12 months, it's portfolio return was 69.04%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| summit therapeutics inc | 16,928,900 |
| definium therapeutics inc | 6,642,610 |
| vir biotechnology inc | 6,545,710 |
| vaxcyte inc | 6,418,480 |
| vertex pharmaceuticals inc | 4,916,400 |
| iqvia hldgs inc | 4,377,420 |
| maplight therapeutics inc | 3,906,190 |
| arvinas inc | 3,313,770 |
New stocks bought by SUPERSTRING CAPITAL MANAGEMENT LP
Additions
| Ticker | % Inc. |
|---|---|
| genmab a/s | 574 |
| travere therapeutics inc | 170 |
| celldex therapeutics inc new | 103 |
| trevi therapeutics inc | 69.64 |
| savara inc | 59.34 |
| zai lab ltd | 40.11 |
| immunovant inc | 23.88 |
| palatin technologies inc | 5.88 |
Additions to existing portfolio by SUPERSTRING CAPITAL MANAGEMENT LP
Reductions
| Ticker | % Reduced |
|---|---|
| century therapeutics inc | -74.23 |
| taysha gene therapies inc | -73.67 |
| bright minds biosciences inc | -71.85 |
| axsome therapeutics inc. | -70.03 |
| protara therapeutics inc | -66.26 |
| oric pharmaceuticals inc | -54.88 |
| cabaletta bio inc | -52.69 |
| urogen pharma ltd | -46.08 |
SUPERSTRING CAPITAL MANAGEMENT LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| dynavax technologies corp | -8,083,600 |
| rezolute inc | -1,212,480 |
| terns pharmaceuticals inc | -17,928,600 |
| mind medicine mindmed inc | -5,693,460 |
| ocular therapeutix inc | -5,075,490 |
| palisade bio inc | -862,692 |
| amicus therapeutics inc | -5,025,240 |
| avalo therapeutics inc | -2,784,160 |
SUPERSTRING CAPITAL MANAGEMENT LP got rid off the above stocks
Sector Distribution
SUPERSTRING CAPITAL MANAGEMENT LP has about 79.7% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 79.7 |
| Others | 20.3 |
Market Cap. Distribution
SUPERSTRING CAPITAL MANAGEMENT LP has about 26.1% of it's portfolio invested in the large-cap and mega-cap stocks.
- SMALL-CAP
- LARGE-CAP
- MID-CAP
- UNALLOCATED
- MICRO-CAP
| Category | % |
|---|---|
| SMALL-CAP | 27.9 |
| LARGE-CAP | 26.1 |
| MID-CAP | 20.7 |
| UNALLOCATED | 20.3 |
| MICRO-CAP | 4.6 |
Stocks belong to which Index?
About 70.4% of the stocks held by SUPERSTRING CAPITAL MANAGEMENT LP either belong to S&P 500 or RUSSELL 2000 index.
- RUSSELL 2000
- Others
- S&P 500
| Index | % |
|---|---|
| RUSSELL 2000 | 62.3 |
| Others | 29.5 |
| S&P 500 | 8.1 |
SUPERSTRING CAPITAL MANAGEMENT LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of SUPERSTRING CAPITAL MANAGEMENT LP
SUPERSTRING CAPITAL MANAGEMENT LP has 35 stocks in it's portfolio. About 57.9% of the portfolio is in top 10 stocks. URGN proved to be the most loss making stock for the portfolio. COGT was the most profitable stock for SUPERSTRING CAPITAL MANAGEMENT LP last quarter.
Last Reported on: 14 May, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACRS | aclaris therapeutics inc | 0.98 | 366,490 | 1,374,340 | new | |||
| ARVN | arvinas inc | 2.37 | 312,620 | 3,313,770 | new | |||
| ASMB | assembly biosciences inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AVTX | avalo therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AXSM | axsome therapeutics inc. | 1.35 | 11,217 | 1,895,900 | reduced | -70.03 | ||
| BLTE | belite bio inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BMEA | biomea fusion inc | 0.27 | 250,000 | 382,500 | unchanged | 0.00 | ||
| CABA | cabaletta bio inc | 2.05 | 1,066,240 | 2,868,180 | reduced | -52.69 | ||
| CAPR | capricor therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CDTX | cidara therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CGEM | cullinan therapeutics inc | 0.60 | 59,484 | 845,268 | new | |||
| CLDX | celldex therapeutics inc new | 4.08 | 180,048 | 5,711,120 | added | 103 | ||
| COGT | cogent biosciences inc | 6.19 | 225,158 | 8,666,330 | reduced | -38.52 | ||
| DRUG | bright minds biosciences inc | 0.69 | 13,311 | 971,304 | reduced | -71.85 | ||
| DVAX | dynavax technologies corp | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ELYM | climb bio inc | 0.98 | 199,209 | 1,364,580 | new | |||
| ENTX | entera bio ltd | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| FOLD | amicus therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| FULC | fulcrum therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| GMAB | genmab a/s | 3.77 | 196,709 | 5,277,700 | added | 574 | ||